HOUSTON, Aug. 26, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that it has engaged argodesign, an award-winning Austin, TX-based product design firm, to
complete the industrial design and ecosystem for the Company's
Rapid Acoustic Pulse ("RAP") device and treatment head system in
preparation for the commercial launch of the product in the first
half of 2021.
"This engagement with argodesign represents a culmination of
years of research and development," commented Dr. Chris Capelli, Soliton President, CEO and
co-founder. "We are excited to join with argodesign to incorporate
the previous engineering work in what we believe will be a
user-friendly and aesthetically pleasing design. The result of this
design effort will be a device that is a more user-focused
iteration of our existing technology incorporating enhanced design
and user interface."
argodesign is a product design consultancy, growth partner to
entrepreneurs, and incubator of new experiences. Founded in
Austin, TX in 2014 and helmed by
renowned design leaders Mark Rolston
and Mark Gauger, argo approaches
technology from a human perspective—where it can add value, and how
it can positively affect the human experience. argo clients have
included Magic Leap, United Rentals, Intel, and many others across
the globe.
"Soliton's technology has the potential to drastically improve
treatments that are often painful, time consuming, expensive, and
ineffective," said Mark Rolston,
Founder and Chief Creative at argodesign. "It has been rewarding to
work alongside the Soliton team for the last few years to translate
this groundbreaking approach into a device that is beautiful,
friendly, and usable in the clinical environment."
------------------------
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
------------------------
"This new device is designed with both the removal of tattoos
and the reduction of cellulite in mind and we are excited to begin
efforts towards a commercially viable platform device," commented
Dr. Chris Capelli, President and CEO
of Soliton.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to create a
user-friendly and aesthetically pleasing design of the Soliton
RAP device for a future commercial launch. These statements
relate to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-engages-argodesign-in-preparation-of-commercial-launch-of-its-rap-device-300906689.html
SOURCE Soliton, Inc.